Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT02933697

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02933697
Other papers using this trial's data
  • A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study Circulation, 2023-01-24 DOI, PubMed 36335915, PMC9875840 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02933697. Randomized; no masking; primary purpose treatment. Start 2017-06-20 (actual); primary completion 2022-07-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
Acronym
AXADIA
Condition
End-stage Kidney Disease
Intervention (Drug)
Apixaban
Intervention (Drug)
Phenprocoumon
Lead sponsor
Atrial Fibrillation Network (class: other)
Collaborator
Bristol-Myers Squibb (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02933697
Content hash
d458e35aa3f92b2c0359265a1755316c64717dec1aac876c0f1ff56cd906e8ed